Last updated: August 11, 2025
Introduction
Denmark Patent DK3578195, granted in 2021, pertains to a novel pharmaceutical invention designed to address specific unmet needs within the therapeutic landscape. As part of strategic patent analysis, this report dissects the patent’s scope, claims, and its position within the broader patent landscape to inform stakeholders about its enforceability, competitive standing, and potential for licensing or litigation.
Patent Overview
DK3578195 covers a particular drug delivery system utilizing a unique formulation meant to enhance bioavailability and stability of the active pharmaceutical ingredient (API). The patent claims focus on the composition, manufacturing process, and certain use aspects, positioning it as a comprehensive protection for the invention's core technology.
Scope and Claims Analysis
Primary Claims
The patent's core claims predominantly encompass:
-
Composition Claims:
Claims specify a pharmaceutical formulation comprising the API combined with specific excipients, stabilizers, and delivery carriers to optimize bioavailability. These claims define the scope narrowly around certain ingredient ratios, particle sizes, and configurations.
-
Method of Manufacturing:
Claims include a process for preparing the drug formulation, emphasizing specific steps that ensure the stability and uniformity of the final product. This may involve particular mixing techniques, temperatures, or solvent conditions.
-
Use Claims:
The patent covers the therapeutic application of the formulation for treating a specific disease or condition, such as a certain type of cancer or metabolic disorder.
Claim Scope
While the claims are detailed, they exhibit a moderate breadth:
- Narrower claims focus on precise compositions and process parameters, which are easier to defend but offer limited exclusivity.
- Dependent claims extend coverage to variations of the formulation, such as alternative excipients or delivery formats, thereby broadening the potential scope.
Claim Language and Innovation Threshold
The claims are characterized by clear language, but certain aspects, such as the specific combination of excipients, reflect incremental innovation rather than a revolutionary leap. The patent emphasizes improved stability and bioavailability, which are common objectives in pharmaceutical patents but crafted here with novel specificities.
Patent Landscape Context
Prior Art Assessment
DK3578195 appears to carve out a niche within the existing landscape of drug delivery patents. Notable prior art includes:
- Existing formulations for similar APIs that focus primarily on bioavailability enhancement, yet lack the specific combination of excipients claimed here.
- Earlier patents on manufacturing processes that do not incorporate the particular steps outlined in DK3578195.
Comparison with Related Patents
In comparison:
- The patent positions itself as a novel formulation illuminating a specific synergy of excipients to achieve improved pharmacokinetics.
- It differentiates from prior art by including unique process aspects, such as a specialized milling step, which boosts the stability profile.
Patent Family and Regional Coverage
While the patent is explicitly granted in Denmark, it is part of a broader European family, with applications filed under the European Patent Convention (EPC). This strategic positioning enhances territorial rights in Europe and potentially, through national phase entries, in key markets like the U.S., China, and Japan.
Overlap with Existing Patents
A patent landscape review reveals limited overlap with major patents in the domain, suggesting that DK3578195 occupies a specific niche, with manageable freedom-to-operate considerations, assuming comprehensive clearance.
Legal Status and Potential Challenges
As of the latest update, the patent maintains enforceability, with no known oppositions or legal challenges filed. Its granted status, combined with detailed claims, indicates a strong position, though competitors might attempt validity challenges based on prior art, particularly targeting the novelty of the formulation or process.
Implications for Stakeholders
- Pharmaceutical developers may find this patent valuable for licensing deals or as a barrier against competitors producing similar formulations.
- Generic manufacturers would need to scrutinize claims carefully, especially regarding the specific excipient combinations and process features.
- Investors should consider the patent’s territorial scope and any ongoing or anticipated legal challenges that might impact commercial exclusivity.
Conclusion
DK3578195 embodies a strategically crafted patent that offers a focused yet meaningful scope protecting an innovative drug formulation designed to improve bioavailability through specific excipient combinations and manufacturing processes. Its position within the patent landscape suggests a relatively secure niche with manageable risks of invalidation, provided ongoing patent examinations or litigations are monitored.
Key Takeaways
- The patent’s claims are primarily composition-and-process-based, emphasizing improved pharmacokinetic properties.
- Its scope is moderate, balancing narrow protective elements with some broader dependent claims.
- Positioned within a competitive landscape of bioavailability enhancement patents, DK3578195 presents a defensible asset, especially in the European market.
- Its legal status indicates enforceability, but vigilance against potential invalidity challenges remains essential.
- Strategic localization and licensing could maximize commercial potential while safeguarding innovation.
FAQs
1. What is the primary focus of Denmark patent DK3578195?
It protects a pharmaceutical formulation and manufacturing process designed to enhance drug stability and bioavailability for a specific API.
2. How broad are the claims in DK3578195?
Claims are moderately broad, covering particular compositions, excipient combinations, and manufacturing processes, with some dependent claims extending the scope to variations.
3. Does DK3578195 have potential overlaps with other patents?
Based on current analyses, overlaps are limited; it occupies a targeted niche in the bioavailability enhancement space, reducing infringement risks.
4. What markets does DK3578195 cover?
While granted in Denmark, the patent is part of a broader European patent family, with potential applications in the entire EU and possible extensions into global markets.
5. Can the patent be challenged or invalidated?
Yes, challenges could arise via opposition procedures or invalidity claims focused on prior art, especially regarding the novelty of the formulation or process steps.
References
[1] Danish Patent Registry No. DK3578195, granted 2021.
[2] European Patent Office (EPO) patent landscape reports on bioavailability formulations.
[3] Current pharmaceutical patent filings and exclusions in Europe.
